Steven Cohen Crinetics Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

$40.1 Billion
Q1 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 778,398 shares of CRNX stock, worth $23.7 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

778,398

Previous 2,788,939 72.09%

Holding current value

$23.7 Million

Previous $143 Million 81.69%

% of portfolio

0.07%

Previous 0.34%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$32.3 - $53.15 $64.9 Million - $107 Million	-2,010,541 Reduced 72.09%	778,398 $26.1 Million
Q4 2024 Feb 14, 2025	BUY	$50.66 - $60.69 $24.7 Million - $29.6 Million	488,296 Added 21.22%	2,788,939 $143 Million
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $21 Million - $26.4 Million	-480,213 Reduced 17.27%	2,300,643 $118 Million
Q2 2024 Aug 14, 2024	SELL	$42.12 - $51.91 $91.3 Million - $113 Million	-2,168,630 Reduced 43.82%	2,780,856 $125 Million
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $53.3 Million - $71.7 Million	1,532,586 Added 44.85%	4,949,486 $232 Million
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $20.7 Million - $30 Million	-808,400 Reduced 19.13%	3,416,900 $122 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $67.5 Million - $129 Million	4,225,300 New	4,225,300 $126 Million
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $17.4 Million - $23.9 Million	-1,134,600 Reduced 83.37%	226,400 $3.64 Million
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $786,892 - $967,740	50,800 Added 3.88%	1,361,000 $24.9 Million
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $409,286 - $505,562	-22,600 Reduced 1.7%	1,310,200 $25.7 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $2.09 Million - $3.5 Million	126,462 Added 10.48%	1,332,800 $24.9 Million
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $1.75 Million - $2.88 Million	101,862 Added 9.22%	1,206,338 $26.5 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $12.7 Million - $18.6 Million	654,676 Added 145.55%	1,104,476 $31.4 Million
Q3 2021 Nov 15, 2021	SELL	$16.88 - $25.23 $4.36 Million - $6.52 Million	-258,333 Reduced 36.48%	449,800 $9.47 Million
Q2 2021 Aug 16, 2021	SELL	$15.9 - $21.15 $9.01 Million - $12 Million	-566,867 Reduced 44.46%	708,133 $13.3 Million
Q1 2021 May 17, 2021	BUY	$13.3 - $17.55 $664,960 - $877,447	49,997 Added 4.08%	1,275,000 $19.5 Million
Q4 2020 Feb 16, 2021	BUY	$12.08 - $17.46 $8.61 Million - $12.4 Million	713,015 Added 139.26%	1,225,003 $17.3 Million
Q3 2020 Nov 16, 2020	BUY	$13.62 - $17.66 $1.6 Million - $2.07 Million	117,156 Added 29.67%	511,988 $8.02 Million
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $5.15 Million - $9.17 Million	394,832 New	394,832 $6.92 Million
Q1 2020 May 15, 2020	SELL	$11.52 - $26.46 $390,124 - $896,067	-33,865 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$15.24 - $25.09 $1.5 Million - $2.46 Million	-98,135 Reduced 74.34%	33,865 $850,000
Q3 2019 Nov 15, 2019	BUY	$14.91 - $25.01 $1.97 Million - $3.3 Million	132,000 New	132,000 $1.99 Million

Others Institutions Holding CRNX

# of Institutions

235

Shares Held

87M

Call Options Held

40K

Put Options Held

162K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.64B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account